NCT04832971 (ARCHES-2) is a Phase 2 clinical trial of ARO-ANG3 in Mixed Dyslipidemia, sponsored by Arrowhead Pharmaceuticals.

Who is sponsoring NCT04832971?

NCT04832971 is sponsored by Arrowhead Pharmaceuticals.

What drugs are being tested in NCT04832971?

Interventions in NCT04832971: ARO-ANG3, Placebo.

What condition does NCT04832971 study?

NCT04832971 studies Mixed Dyslipidemia.

Is NCT04832971 still recruiting?

NCT04832971 is currently completed. Last updated 3 December 2025.

Are results published for NCT04832971?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-12-03 · How we verify

NCT04832971: ARCHES-2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

Completed Phase 2 Results posted Last updated 3 December 2025

What this trial tests

Phase 2 trial testing ARO-ANG3 in Mixed Dyslipidemia in 204 participants. Completed in 25 September 2024.

Timeline

28 June 2021

Primary endpoint
30 August 2022

25 September 2024

Quick facts

Lead sponsor	Arrowhead Pharmaceuticals
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	204
Start date	28 June 2021
Primary completion	30 August 2022
Estimated completion	25 September 2024
Sites	24 locations across New Zealand, Canada, United States, Australia

Drugs / interventions tested

ARO-ANG3 — full drug profile →
Placebo

Conditions studied

Mixed Dyslipidemia — all drugs for Mixed Dyslipidemia →

Sponsor

Arrowhead Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Mixed Dyslipidemia. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percent Change From Baseline in Fasting TG at Week 24 Primary · Baseline, Week 24

Group	Value	95% CI
Placebo	7.55	± 3.774
ARO-ANG3 50 mg	-43.67	± 3.770
ARO-ANG3 100 mg	-49.01	± 3.777
ARO-ANG3 200 mg	-55.57	± 3.726

Percent Change From Baseline in Fasting TG Over Time Secondary · Baseline, up to Week 36 (double-blind treatment period)

Week 4

Group	Value	95% CI
Placebo	7.00	± 3.583
ARO-ANG3 50 mg	-41.52	± 3.604
ARO-ANG3 100 mg	-52.22	± 3.658
ARO-ANG3 200 mg	-56.21	± 3.619

Week 8

Group	Value	95% CI
Placebo	13.58	± 4.188
ARO-ANG3 50 mg	-41.01	± 4.217
ARO-ANG3 100 mg	-47.73	± 4.250
ARO-ANG3 200 mg	-52.55	± 4.257

Week 12

Group	Value	95% CI
Placebo	2.17	± 4.305
ARO-ANG3 50 mg	-42.79	± 4.269
ARO-ANG3 100 mg	-41.71	± 4.274
ARO-ANG3 200 mg	-49.84	± 4.183

Week 16

Group	Value	95% CI
Placebo	17.18	± 6.952
ARO-ANG3 50 mg	-48.48	± 6.947
ARO-ANG3 100 mg	-51.99	± 6.942
ARO-ANG3 200 mg	-58.73	± 6.820

Week 20

Group	Value	95% CI
Placebo	11.54	± 5.930
ARO-ANG3 50 mg	-48.70	± 5.928
ARO-ANG3 100 mg	-52.73	± 5.942
ARO-ANG3 200 mg	-57.97	± 5.790

Week 24

Group	Value	95% CI
Placebo	7.55	± 3.774
ARO-ANG3 50 mg	-43.67	± 3.770
ARO-ANG3 100 mg	-49.01	± 3.777
ARO-ANG3 200 mg	-55.57	± 3.726

Week 28

Group	Value	95% CI
Placebo	7.24	± 3.950
ARO-ANG3 50 mg	-41.38	± 3.966
ARO-ANG3 100 mg	-43.95	± 4.039
ARO-ANG3 200 mg	-54.39	± 3.920

Week 36

Group	Value	95% CI
Placebo	-0.43	± 3.798
ARO-ANG3 50 mg	-34.49	± 3.809
ARO-ANG3 100 mg	-38.33	± 3.850
ARO-ANG3 200 mg	-51.63	± 3.750

Percent Change From Baseline in Fasting Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 24 Secondary · Baseline, Week 24

Group	Value	95% CI
Placebo	4.2	± 3.31
ARO-ANG3 50 mg	-25.1	± 3.31
ARO-ANG3 100 mg	-24.6	± 3.31
ARO-ANG3 200 mg	-32.2	± 3.26

Percent Change From Baseline in Fasting Non-HDL-C Over Time Secondary · Baseline, up to Week 36 (double-blind treatment period)

Week 4

Group	Value	95% CI
Placebo	5.2	± 2.51
ARO-ANG3 50 mg	-23.5	± 2.52
ARO-ANG3 100 mg	-25.3	± 2.55
ARO-ANG3 200 mg	-32.9	± 2.50

Week 8

Group	Value	95% CI
Placebo	3.7	± 3.02
ARO-ANG3 50 mg	-24.4	± 3.04
ARO-ANG3 100 mg	-22.8	± 3.04
ARO-ANG3 200 mg	-30.3	± 3.02

Week 12

Group	Value	95% CI
Placebo	3.4	± 3.06
ARO-ANG3 50 mg	-22.8	± 3.04
ARO-ANG3 100 mg	-18.4	± 3.04
ARO-ANG3 200 mg	-28.1	± 2.97

Week 16

Group	Value	95% CI
Placebo	2.5	± 2.86
ARO-ANG3 50 mg	-26.8	± 2.86
ARO-ANG3 100 mg	-28.3	± 2.85
ARO-ANG3 200 mg	-37.0	± 2.81

Week 20

Group	Value	95% CI
Placebo	0.8	± 2.71
ARO-ANG3 50 mg	-28.1	± 2.70
ARO-ANG3 100 mg	-26.5	± 2.69
ARO-ANG3 200 mg	-34.1	± 2.64

Week 24

Group	Value	95% CI
Placebo	4.2	± 3.31
ARO-ANG3 50 mg	-25.1	± 3.31
ARO-ANG3 100 mg	-24.6	± 3.31
ARO-ANG3 200 mg	-32.2	± 3.26

Week 28

Group	Value	95% CI
Placebo	1.2	± 3.00
ARO-ANG3 50 mg	-23.1	± 3.01
ARO-ANG3 100 mg	-22.3	± 3.04
ARO-ANG3 200 mg	-30.0	± 2.96

Week 36

Group	Value	95% CI
Placebo	-1.5	± 3.19
ARO-ANG3 50 mg	-20.2	± 3.21
ARO-ANG3 100 mg	-17.3	± 3.23
ARO-ANG3 200 mg	-24.1	± 3.14

Percent Change From Baseline in Fasting Total Apolipoprotein B (ApoB) at Week 24 Secondary · Baseline, Week 24

Group	Value	95% CI
Placebo	2.27	± 2.807
ARO-ANG3 50 mg	-16.40	± 2.835
ARO-ANG3 100 mg	-12.91	± 2.805
ARO-ANG3 200 mg	-19.64	± 2.788

Percent Change From Baseline in Fasting Total ApoB Over Time Secondary · Baseline, up to Week 36 (double-blind treatment period)

Week 4

Group	Value	95% CI
Placebo	2.57	± 2.074
ARO-ANG3 50 mg	-14.00	± 2.116
ARO-ANG3 100 mg	-11.71	± 2.093
ARO-ANG3 200 mg	-18.47	± 2.105

Week 8

Group	Value	95% CI
Placebo	1.51	± 2.518
ARO-ANG3 50 mg	-15.85	± 2.553
ARO-ANG3 100 mg	-10.66	± 2.525
ARO-ANG3 200 mg	-15.05	± 2.556

Week 12

Group	Value	95% CI
Placebo	2.26	± 2.656
ARO-ANG3 50 mg	-14.96	± 2.653
ARO-ANG3 100 mg	-7.69	± 2.617
ARO-ANG3 200 mg	-15.10	± 2.606

Week 16

Group	Value	95% CI
Placebo	-1.36	± 2.524
ARO-ANG3 50 mg	-15.72	± 2.543
ARO-ANG3 100 mg	-14.33	± 2.513
ARO-ANG3 200 mg	-21.66	± 2.509

Week 20

Group	Value	95% CI
Placebo	-0.28	± 2.350
ARO-ANG3 50 mg	-17.99	± 2.370
ARO-ANG3 100 mg	-14.52	± 2.329
ARO-ANG3 200 mg	-18.58	± 2.326

Week 24

Group	Value	95% CI
Placebo	2.27	± 2.807
ARO-ANG3 50 mg	-16.40	± 2.835
ARO-ANG3 100 mg	-12.91	± 2.805
ARO-ANG3 200 mg	-19.64	± 2.788

Week 28

Group	Value	95% CI
Placebo	0.51	± 2.688
ARO-ANG3 50 mg	-15.39	± 2.725
ARO-ANG3 100 mg	-12.47	± 2.703
ARO-ANG3 200 mg	-17.03	± 2.680

Week 36

Group	Value	95% CI
Placebo	-2.30	± 2.777
ARO-ANG3 50 mg	-12.85	± 2.801
ARO-ANG3 100 mg	-9.07	± 2.791
ARO-ANG3 200 mg	-13.21	± 2.756

Percent Change From Baseline in Fasting Low-density Lipoprotein-Cholesterol (LDL-C) Using Ultracentrifugation at Week 24 Secondary · Baseline, Week 24

Group	Value	95% CI
Placebo	5.0	± 4.53
ARO-ANG3 50 mg	-11.0	± 4.58
ARO-ANG3 100 mg	-4.3	± 4.56
ARO-ANG3 200 mg	-15.1	± 4.51

Percent Change From Baseline in Fasting LDL-C Using Ultracentrifugation Over Time Secondary · Baseline, up to Week 36 (double-blind treatment period)

Week 4

Group	Value	95% CI
Placebo	5.1	± 3.95
ARO-ANG3 50 mg	-8.3	± 4.03
ARO-ANG3 100 mg	-3.4	± 4.02
ARO-ANG3 200 mg	-13.7	± 3.98

Week 8

Group	Value	95% CI
Placebo	3.7	± 4.78
ARO-ANG3 50 mg	-10.1	± 4.85
ARO-ANG3 100 mg	-0.7	± 4.83
ARO-ANG3 200 mg	-10.8	± 4.81

Week 12

Group	Value	95% CI
Placebo	7.7	± 7.31
ARO-ANG3 50 mg	-7.6	± 7.36
ARO-ANG3 100 mg	7.9	± 7.34
ARO-ANG3 200 mg	-12.1	± 7.23

Week 16

Group	Value	95% CI
Placebo	3.6	± 4.51
ARO-ANG3 50 mg	-9.5	± 4.56
ARO-ANG3 100 mg	-7.4	± 4.52
ARO-ANG3 200 mg	-19.5	± 4.48

Week 20

Group	Value	95% CI
Placebo	1.8	± 4.26
ARO-ANG3 50 mg	-12.2	± 4.31
ARO-ANG3 100 mg	-6.9	± 4.28
ARO-ANG3 200 mg	-15.3	± 4.22

Week 24

Group	Value	95% CI
Placebo	5.0	± 4.53
ARO-ANG3 50 mg	-11.0	± 4.58
ARO-ANG3 100 mg	-4.3	± 4.56
ARO-ANG3 200 mg	-15.1	± 4.51

Week 28

Group	Value	95% CI
Placebo	0.2	± 4.67
ARO-ANG3 50 mg	-9.1	± 4.75
ARO-ANG3 100 mg	-2.4	± 4.74
ARO-ANG3 200 mg	-11.3	± 4.66

Week 36

Group	Value	95% CI
Placebo	3.1	± 5.75
ARO-ANG3 50 mg	-8.9	± 5.81
ARO-ANG3 100 mg	3.7	± 5.82
ARO-ANG3 200 mg	-4.4	± 5.71

Percent Change From Baseline in Angiopoietin-like Protein 3 (ANGPTL3) at Week 24 Secondary · Baseline, Week 24

Group	Value	95% CI
Placebo	1.24	± 2.801
ARO-ANG3 50 mg	-53.02	± 2.829
ARO-ANG3 100 mg	-68.52	± 2.807
ARO-ANG3 200 mg	-72.45	± 2.761

Percent Change From Baseline in ANGPTL3 Over Time Secondary · Baseline, up to Week 36 (double-blind treatment period)

Week 4

Group	Value	95% CI
Placebo	5.54	± 2.353
ARO-ANG3 50 mg	-62.11	± 2.388
ARO-ANG3 100 mg	-75.25	± 2.401
ARO-ANG3 200 mg	-79.15	± 2.365

Week 8

Group	Value	95% CI
Placebo	2.97	± 3.023
ARO-ANG3 50 mg	-56.09	± 3.074
ARO-ANG3 100 mg	-69.01	± 3.066
ARO-ANG3 200 mg	-73.47	± 3.045

Week 12

Group	Value	95% CI
Placebo	7.38	± 3.599
ARO-ANG3 50 mg	-47.72	± 3.635
ARO-ANG3 100 mg	-63.17	± 3.608
ARO-ANG3 200 mg	-66.62	± 3.542

Week 16

Group	Value	95% CI
Placebo	8.48	± 2.379
ARO-ANG3 50 mg	-63.73	± 2.400
ARO-ANG3 100 mg	-75.61	± 2.379
ARO-ANG3 200 mg	-80.52	± 2.345

Week 20

Group	Value	95% CI
Placebo	4.35	± 2.338
ARO-ANG3 50 mg	-60.50	± 2.360
ARO-ANG3 100 mg	-73.10	± 2.347
ARO-ANG3 200 mg	-76.25	± 2.299

Week 24

Group	Value	95% CI
Placebo	1.24	± 2.801
ARO-ANG3 50 mg	-53.02	± 2.829
ARO-ANG3 100 mg	-68.52	± 2.807
ARO-ANG3 200 mg	-72.45	± 2.761

Week 28

Group	Value	95% CI
Placebo	5.18	± 2.879
ARO-ANG3 50 mg	-49.57	± 2.920
ARO-ANG3 100 mg	-61.43	± 2.921
ARO-ANG3 200 mg	-68.19	± 2.852

Week 36

Group	Value	95% CI
Placebo	3.73	± 3.110
ARO-ANG3 50 mg	-41.70	± 3.158
ARO-ANG3 100 mg	-53.41	± 3.155
ARO-ANG3 200 mg	-59.85	± 3.066

Percent Change From Baseline in Fasting High-Density Lipoprotein-Cholesterol (HDL-C) at Week 24 Secondary · Baseline, Week 24

Group	Value	95% CI
Placebo	3.1	± 2.91
ARO-ANG3 50 mg	-9.0	± 2.94
ARO-ANG3 100 mg	-18.5	± 2.96
ARO-ANG3 200 mg	-21.5	± 2.89

Percent Change From Baseline in Fasting HDL-C Over Time Secondary · Baseline, up to Week 36 (double-blind treatment period)

Week 4

Group	Value	95% CI
Placebo	-0.3	± 2.59
ARO-ANG3 50 mg	-13.9	± 2.63
ARO-ANG3 100 mg	-25.5	± 2.68
ARO-ANG3 200 mg	-24.8	± 2.61

Week 8

Group	Value	95% CI
Placebo	0.4	± 2.67
ARO-ANG3 50 mg	-14.5	± 2.71
ARO-ANG3 100 mg	-25.0	± 2.74
ARO-ANG3 200 mg	-25.8	± 2.69

Week 12

Group	Value	95% CI
Placebo	2.0	± 3.10
ARO-ANG3 50 mg	-7.0	± 3.11
ARO-ANG3 100 mg	-18.7	± 3.14
ARO-ANG3 200 mg	-18.2	± 3.05

Week 16

Group	Value	95% CI
Placebo	2.1	± 2.99
ARO-ANG3 50 mg	-15.8	± 3.02
ARO-ANG3 100 mg	-28.5	± 3.04
ARO-ANG3 200 mg	-30.2	± 2.96

Week 20

Group	Value	95% CI
Placebo	3.4	± 2.89
ARO-ANG3 50 mg	-11.3	± 2.92
ARO-ANG3 100 mg	-25.1	± 2.94
ARO-ANG3 200 mg	-27.1	± 2.86

Week 24

Group	Value	95% CI
Placebo	3.1	± 2.91
ARO-ANG3 50 mg	-9.0	± 2.94
ARO-ANG3 100 mg	-18.5	± 2.96
ARO-ANG3 200 mg	-21.5	± 2.89

Week 28

Group	Value	95% CI
Placebo	3.0	± 2.78
ARO-ANG3 50 mg	-5.5	± 2.82
ARO-ANG3 100 mg	-14.7	± 2.87
ARO-ANG3 200 mg	-18.6	± 2.77

Week 36

Group	Value	95% CI
Placebo	6.4	± 2.78
ARO-ANG3 50 mg	-1.4	± 2.82
ARO-ANG3 100 mg	-13.7	± 2.86
ARO-ANG3 200 mg	-9.4	± 2.75

Adverse events — posted to ClinicalTrials.gov

Time frame: All-cause mortality: From randomization through Month 24. Adverse events: From first dose of study drug through Week 36 (double-blind period); from first dose of open-label study drug up to Month 24 (open-label extension).. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Placebo

Serious: 4/51 (8%)

Deaths: 1/51

ARO-ANG3 50 mg

Serious: 5/50 (10%)

Deaths: 0/50

ARO-ANG3 100 mg

Serious: 0/51 (0%)

Deaths: 0/51

ARO-ANG3 200 mg

Serious: 1/52 (2%)

Deaths: 0/52

Placebo/ARO-ANG3 50 mg

Serious: 3/13 (23%)

Deaths: 0/13

ARO-ANG3 50 mg/ARO-ANG3 50 mg

Serious: 4/36 (11%)

Deaths: 0/36

Placebo/ARO-ANG3 100 mg

Serious: 2/14 (14%)

Deaths: 0/14

ARO-ANG3 100 mg/ARO-ANG3 100 mg

Serious: 5/39 (13%)

Deaths: 1/39

Placebo/ARO-ANG3 200 mg

Serious: 2/13 (15%)

Deaths: 0/13

ARO-ANG3 200mg/ARO-ANG3 200 mg

Serious: 5/41 (12%)

Deaths: 0/41

Serious adverse events (40 terms)

Reaction	System	Placebo	ARO-ANG3 50 mg	ARO-ANG3 100 mg	ARO-ANG3 200 mg	Placebo/ARO-ANG3 50 mg	ARO-ANG3 50 mg/ARO-ANG3 50…	Placebo/ARO-ANG3 100 mg	ARO-ANG3 100 mg/ARO-ANG3 1…	Placebo/ARO-ANG3 200 mg	ARO-ANG3 200mg/ARO-ANG3 20…
Acute kidney injury	Renal and urinary disorders	—	—	—	—	—	—	—	—	—	—
Acute myocardial infarction	Cardiac disorders	—	—	—	—	—	—	—	—	—	—
Angina unstable	Cardiac disorders	—	—	—	—	—	—	—	—	—	—
Arteriosclerosis coronary artery	Cardiac disorders	—	—	—	—	—	—	—	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—	—	—	—	—	—	—	—
Bundle branch block left	Cardiac disorders	—	—	—	—	—	—	—	—	—	—
Cardiac failure	Cardiac disorders	—	—	—	—	—	—	—	—	—	—
Coronary artery stenosis	Cardiac disorders	—	—	—	—	—	—	—	—	—	—
Myocardial infarction	Cardiac disorders	—	—	—	—	—	—	—	—	—	—
Silent myocardial infarction	Cardiac disorders	—	—	—	—	—	—	—	—	—	—
Supraventricular tachycardia	Cardiac disorders	—	—	—	—	—	—	—	—	—	—
Incarcerated umbilical hernia	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Inguinal hernia	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Pancreatitis	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Pancreatitis acute	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Small intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Death	General disorders	—	—	—	—	—	—	—	—	—	—
Non-cardiac chest pain	General disorders	—	—	—	—	—	—	—	—	—	—
COVID-19 pneumonia	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Cellulitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Influenza	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Pyelonephritis	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Sepsis	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Ankle fracture	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—	—

Other adverse events (189 terms — click to expand)

Reaction	System	Placebo	ARO-ANG3 50 mg	ARO-ANG3 100 mg	ARO-ANG3 200 mg	Placebo/ARO-ANG3 50 mg	ARO-ANG3 50 mg/ARO-ANG3 50…	Placebo/ARO-ANG3 100 mg	ARO-ANG3 100 mg/ARO-ANG3 1…	Placebo/ARO-ANG3 200 mg	ARO-ANG3 200mg/ARO-ANG3 20…
COVID-19	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—
Injection site pain	General disorders	—	—	—	—	—	—	—	—	—	—
Type 2 diabetes mellitus	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—
Injection site erythema	General disorders	—	—	—	—	—	—	—	—	—	—
Musculoskeletal chest pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Gastroenteritis	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Lower respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Sinusitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Fall	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—	—
Blood glucose increased	Investigations	—	—	—	—	—	—	—	—	—	—
Glycosylated haemoglobin increased	Investigations	—	—	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—
Cataract	Eye disorders	—	—	—	—	—	—	—	—	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—	—
Influenza like illness	General disorders	—	—	—	—	—	—	—	—	—	—
Non-cardiac chest pain	General disorders	—	—	—	—	—	—	—	—	—	—
Conjunctivitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Diverticulitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Influenza	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Viral upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Contusion	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—	—
Muscle strain	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—	—
Skin laceration	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—	—
Amylase increased	Investigations	—	—	—	—	—	—	—	—	—	—
Blood creatine phosphokinase increased	Investigations	—	—	—	—	—	—	—	—	—	—
Lipase increased	Investigations	—	—	—	—	—	—	—	—	—	—

Most-reported serious reactions: Acute kidney injury, Acute myocardial infarction, Angina unstable, Arteriosclerosis coronary artery, Atrial fibrillation, Bundle branch block left, Cardiac failure, Coronary artery stenosis.

Data from ClinicalTrials.gov NCT04832971 adverse events section.

Sponsor's own description

The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will initially receive 2 subcutaneous injections of ARO-ANG3 or placebo. Participants who complete the double-blind treatment period may opt to continue in an open-label extension during which they will receive up to 8 doses of ARO-ANG3.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic siRNA: State-of-the-Art and Future Perspectives.
Friedrich M, Aigner A. · · 2022 · cited 256× · PMID 35997897 · DOI 10.1007/s40259-022-00549-3
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.
Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, et al · · 2024 · cited 143× · PMID 38809174 · DOI 10.1056/nejmoa2404147
Where should siRNAs go: applicable organs for siRNA drugs.
Ahn I, Kang CS, Han J. · · 2023 · cited 100× · PMID 37430086 · DOI 10.1038/s12276-023-00998-y
RNA therapeutics: updates and future potential.
Zhang C, Zhang B. · · 2023 · cited 81× · PMID 36100838 · DOI 10.1007/s11427-022-2171-2
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts.
Watts GF, Schwabe C, Scott R, Gladding PA, et al · · 2023 · cited 76× · PMID 37626170 · DOI 10.1038/s41591-023-02494-2
Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.
Liu M, Wang Y, Zhang Y, Hu D, et al · · 2025 · cited 62× · PMID 40059188 · DOI 10.1038/s41392-024-02112-8
Small non-coding RNA therapeutics for cardiovascular disease.
Shah AM, Giacca M. · · 2022 · cited 60× · PMID 36106499 · DOI 10.1093/eurheartj/ehac463
Updates in Drug Treatment of Severe Hypertriglyceridemia.
Gouni-Berthold I, Schwarz J, Berthold HK. · · 2023 · cited 38× · PMID 37642858 · DOI 10.1007/s11883-023-01140-z

Verify or expand the search:

Other trials of ARO-ANG3

Trials testing the same drug.

NCT03747224 — Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients · Phase 1 · completed

Other recruiting trials for Mixed Dyslipidemia

Currently open trials in the same condition.

NCT07206472 — A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholestero · active not recruiting
NCT06686615 — A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary · recruiting
NCT06386419 — A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hyperchol · Phase 4 · active not recruiting
NCT06497127 — A Study in Patients With Mixed Dyslipidemia · Phase 2 · active not recruiting
NCT05399992 — Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD · active not recruiting

Other Arrowhead Pharmaceuticals trials

Trials by the same sponsor.

NCT07037771 — A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) · Phase 3 · recruiting
NCT05537025 — Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis · Phase 1, PHASE2 · completed
NCT05533294 — Study of ARO-RAGE in Healthy Subjects · Phase 1 · completed
NCT05413135 — Study of ARO-APOC3 in Adults With Dyslipidemia · Phase 2 · completed
NCT05276570 — Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04832971 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arrowhead Pharmaceuticals
Last refreshed: 3 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04832971.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT04832971: ARCHES-2

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (40 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of ARO-ANG3

Other recruiting trials for Mixed Dyslipidemia

Other Arrowhead Pharmaceuticals trials

Verify against primary sources